Reconsideration of age as a contraindication for curative therapy of sickle cell disease

JAMA. 2014 Jul 2;312(1):33-4. doi: 10.1001/jama.2014.7193.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Alemtuzumab
  • Anemia, Sickle Cell / therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Sirolimus / administration & dosage*
  • beta-Thalassemia / therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Alemtuzumab
  • Sirolimus